The Dietary Supplement Health and Education Act passed the US Congress in October 1994. The bill was a compromise: pre-market approval was off the table, but post-market enforcement was preserved, label disclosures were standardized, and a structured set of permitted claims defined the line between supplement and drug. The Senate vote was 95 to 5. The President signed it into law on the twenty-fifth of October. The supplement industry did $8.5 billion in retail sales that year and $43.4 billion by 2014.
Twenty-five years of market reorganization happened underneath that revenue growth. The reorganization produced specific structures that did not exist in 1994 and that the peptide category, in 2026, does not yet have. The market that did the work is now the market the peptide market will be measured against, on a roughly compressed timeline.
What did the decade after DSHEA actually produce?
Three things in sequence.
First, a period of rapid entry. The regulatory gap created by no pre-market approval meant that supplements could be brought to market quickly and cheaply. The industry's product count grew from roughly four thousand SKUs in 1994 to more than fifty thousand by 2000. Quality varied wildly. Independent laboratory testing in the late 1990s found that the labelled potency of randomly sampled supplements was substantially off in roughly a third of cases.
Second, a period of enforcement against the worst actors. The FDA used its post-market enforcement authority to issue warning letters and pursue legal action against the most clearly misbranded products. The cases tended to cluster around specific commercial structures (mail-order pyramid schemes, telephone-sales operations, online retailers without pharmacy registration) rather than around specific ingredients. The enforcement was not comprehensive (the agency's resources were not sufficient for that), but it produced visible deterrence in the categories it touched.
Third, a period of market-side response. Two specific structures emerged to fill the regulatory gap that the post-market enforcement could not close on its own. USP Verified, launched in 2001 by the United States Pharmacopeia, offered voluntary third-party certification that a supplement met identity, purity, potency, and contamination standards. NSF Certified for Sport, operated by NSF International, layered on additional testing for substances banned by major sports leagues and the World Anti-Doping Agency. Both certifications carried licensable marks; suppliers paid for the testing and for the right to display the mark; buyers used the mark as a credibility signal independent of the supplier's own marketing.
By 2010 a buyer wanting to evaluate a supplement had three working signals: the FDA's enforcement record (publicly available, sparse, lagged), the supplier's own marketing (high-volume, low-evidence-value), and the third-party certification marks (limited coverage, high-evidence-value). The third-party marks did most of the work for the buyer who wanted to make a defensible purchase.
Where is the peptide category on the same curve?
Roughly at year four to five post-DSHEA, but on a compressed timeline. The compression is driven by three factors.
The agency is faster. The FDA's enforcement infrastructure is more sophisticated than in 1994, the warning-letter system is more responsive, and the agency's public communications cadence is significantly tighter. A warning letter issued in 2025 is on the public record within a week; the equivalent letter in 1996 might have been buried in agency archives for months.
The information flow is faster. Independent laboratory testing of peptide vendors is happening at a pace that produces a documented failure within weeks of a problematic product entering distribution. The peptide forums on Reddit and adjacent platforms produce real-time discussion of test results, vendor exits, and warning letters. The discussion is messy but it is fast.
The institutional models exist. USP, NSF, and ConsumerLab took years to figure out the certification-mark model in the supplement category. The same institutional template can be applied to peptides without re-inventing the institutional form. The cost of standing up a new third-party verification body is lower than it was in 2000 because the playbook is documented.
The compression suggests the peptide category will go through roughly twenty-five years of supplement-category reorganization in seven to ten years, with the third-party verification phase running 2025 to 2028. The suppliers who participate early in that phase capture the position; the suppliers who wait are competing in the residual market.
Which two structures are emerging that the peptide category will need?
A peptide-category equivalent of USP Verified. A third-party laboratory certification that tests peptide lots for identity, purity, and absence of contaminants, with a licensable mark that suppliers can display on their products and websites. The institutional model is direct: an accredited laboratory, a published testing methodology, a fee structure that funds the testing, and a licensing arrangement that produces the mark.
A peptide-category equivalent of NSF Certified for Sport, or a generalized chain-of-custody attestation. A registry that records a lot's full history from manufacturing through distribution to consumer, with the entry queryable by the current holder. PuraTrust's verified-lot registry is one implementation of this structure. The structure is not a substitute for the laboratory certification; it is layered on top, adding the chain-of-custody dimension that lab certification alone does not cover.
Both structures exist in early form in 2026. Neither is universal yet. The supplier who participates in both is operating with the credibility signal that the post-DSHEA supplement market eventually demanded. The supplier who is not is operating in the pre-2001 supplement market, with the disadvantages that implies.
What should a working operator take from this?
The historical analog says the next twelve months will be the window in which the post-hoc enforcement structures harden and the market-side verification structures consolidate. By the end of 2027 the peptide category will have a working third-party certification regime, and the suppliers who participated in standing it up will hold the credibility positions that result.
The supplier participating in the verification regime now is making the same investment that supplement suppliers made in 1999 to 2002. The cost is in the range of fifty to two hundred thousand dollars for an established mid-size supplier, depending on product breadth. The competitive return is durable.
The buyer in 2026 should look for the same signals the supplement buyer in 2005 learned to look for: third-party laboratory certification with a recognized mark, chain-of-custody documentation that travels with the product, public enforcement record from the regulating agency. The peptide buyer in 2030 will not be evaluating individual posts on Reddit. The peptide buyer in 2030 will be querying the registry. The market is moving toward that buyer. The supplier who arrives there first will already be the supplier of record.
This has happened before, in a category roughly twenty times the size. The peptide market will not be the exception that rewrites the pattern. It will be the next data point on the same curve. The curve is published.